title: Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex.
abstract: mAb B4 is a monoclonal antibody directed against HIV receptor complex. The antibody had broad neutralizing activity against HIV and provided postexposure prophylaxis to hu-peripheral blood leukocyte (PBL)-severe combined immunodeficient mice and chimpanzees. B4 recognized a complex receptor site for HIV on the T cell surface that includes CD4 and also may be influenced by interaction with HIV coreceptors. mAb B4 preferentially neutralized primary HIV-1 isolates compared with T cell line-adapted strains, including syncytium-inducing and non-syncytium-inducing phenotypes, representatives from HIV-1 subtypes A-G, as well as HIV-2, simian immunodeficiency virus, and chimeric simian/human immunodeficiency virus (SHIV). Neutralization was demonstrated in both pre- and postinfection models. The administration of mAb B4 after infectious challenge totally interrupted the infection of hu-PBL-severe combined immunodeficient mice by PBL-grown HIV-1 and the infection of chimpanzees by chimp-adapted HIV-1. This mode of protection suggested that the anti-HIV receptor antibody is efficacious for prophylaxis after exposure to HIV and for prevention of maternal transmission and may be an effective antiretroviral agent for treatment.
authors.affiliation: United Biomedical Inc., 25 Davids Drive, Hauppauge, NY 11788, USA. pr@unitedbiomedical.com
authors.forename: C Y
authors.initials: CY
authors.lastname: Wang
authors.forename: L S
authors.initials: LS
authors.lastname: Sawyer
authors.forename: K K
authors.initials: KK
authors.lastname: Murthy
authors.forename: X
authors.initials: X
authors.lastname: Fang
authors.forename: A M
authors.initials: AM
authors.lastname: Walfield
authors.forename: J
authors.initials: J
authors.lastname: Ye
authors.forename: J J
authors.initials: JJ
authors.lastname: Wang
authors.forename: P D
authors.initials: PD
authors.lastname: Chen
authors.forename: M L
authors.initials: ML
authors.lastname: Li
authors.forename: M T
authors.initials: MT
authors.lastname: Salas
authors.forename: M
authors.initials: M
authors.lastname: Shen
authors.forename: M C
authors.initials: MC
authors.lastname: Gauduin
authors.forename: R W
authors.initials: RW
authors.lastname: Boyle
authors.forename: R A
authors.initials: RA
authors.lastname: Koup
authors.forename: D C
authors.initials: DC
authors.lastname: Montefiori
authors.forename: J R
authors.initials: JR
authors.lastname: Mascola
authors.forename: W C
authors.initials: WC
authors.lastname: Koff
authors.forename: C V
authors.initials: CV
authors.lastname: Hanson
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D015704:CD4 Antigens / Q000276:immunology*; D015497:HIV-1 / Q000145:classification / Q000276:immunology* / Q000302:isolation & purification; D018451:Homosexuality, Male; D006801:Humans; D007167:Immunotherapy; D007962:Leukocytes / Q000276:immunology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D009500:Neutralization Tests; D002679:Pan troglodytes; D015728:Receptors, HIV / Q000276:immunology*; D010948:Viral Plaque Assay
chemical_list: D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D015728:Receptors, HIV